Dr. Chatzkel on Future Treatment Options in Bladder Cancer

Jonathan A. Chatzkel, MD, assistant professor of medicine, Division of Hematology and Oncology, University of Florida College of Medicine, University of Florida Health, discusses the future treatment options in bladder cancer.

Maintenance immunotherapies have carved out a role in the bladder cancer treatment paradigm, Chatzkel says. The utilization of nivolumab (Opdivo) in the maintenance setting has provided a boost to overall survival, giving patients a benefit from this therapy, Chatzkel explains. Furthermore, enfortumab vedotin- ejfv (Padcev) and other antibody drug conjugates have provided other options in later-line settings, Chatzkel adds.

Therapies such as enfortumab vedotin, sacituzumab govitecan-hziy (Trodelvy), or erdafitinib (Balversa) could shift into frontline settings as patients continue to benefit and researchers learn more about the efficacy of these agents, Chatzkel concludes.